Rules-Based Medicine Newswire (Page 2)

Comprehensive Real-Time News Feed for Rules-Based Medicine. (Page 2)

Results 21 - 40 of 121 in Rules-Based Medicine

  1. Myriad Genetics' Tumor BRACAnalysis CDx identifies 44% more candidates for PARP therapyRead the original story w/Photo

    Sep 29, 2014 | Medical News

    Myriad Genetics , Inc. today announced that its Tumor BRACAnalysis CDx- companion diagnostic test significantly improved the detection of cancer-causing BRCA1 /2 mutations by 44 percent in women with ovarian cancer. Data from this new study were presented at the 2014 European Society for Medical Oncology annual meeting in Madrid, Spain.

    Comment?

  2. Myriad Presents Tumor BRACAnalysis CDx(TM) Study at ESMORead the original story w/Photo

    Sep 29, 2014 | GlobeNewswire

    Myriad Genetics, Inc. today announced that its Tumor BRACAnalysis CDx companion diagnostic test significantly improved the detection of cancer-causing BRCA 1/2 mutations by 44 percent in women with ovarian cancer. Data from this new study were presented at the 2014 European Society for Medical Oncology annual meeting in Madrid, Spain.

    Comment?

  3. Myriad Genetics CFO Unloads $333,844 in StockRead the original story w/Photo

    Sep 26, 2014 | AmericanBankingNews.com

    Myriad Genetics CFO James S. Evans unloaded 8,790 shares of the company's stock on the open market in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $37.98, for a total value of $333,844.20.

    Comment?

  4. Myriad Genetics's "Neutral" Rating Reiterated at ZacksRead the original story w/Photo

    Sep 25, 2014 | AmericanBankingNews.com

    's stock had its "neutral" rating reiterated by Zacks in a note issued to investors on Thursday. They currently have a $40.00 target price on the stock.

    Comment?

  5. Insider Selling: Myriad Genetics CFO Unloads 110,463 Shares of StockRead the original story w/Photo

    Sep 23, 2014 | AmericanBankingNews.com

    Myriad Genetics CFO James S. Evans sold 110,463 shares of the company's stock in a transaction dated Tuesday, September 23rd. The stock was sold at an average price of $37.89, for a total transaction of $4,185,443.07.

    Comment?

  6. Quest Diagnostics Offers A Good Long-Term OpportunityRead the original story w/Photo

    Sep 11, 2014 | Seeking Alpha

    Quest Diagnostics Q2 FY2014 revenue from continuing operations grew 4.8% to $1.9 billion, while EPS grew 1.9% to $1.08. Quest Diagnostics and Lab Corps have perfected the game of consolidating and standardizing lab tests, and eliminate smaller competitors through acquisitions.

    Comment?

  7. Myriad myPath(TM) Melanoma Test Reduced Indeterminate Cases by 76...Read the original story w/Photo

    Sep 9, 2014 | GlobeNewswire

    Myriad Genetics, Inc. today presented results from a pivotal clinical utility study of the Myriad myPath Melanoma test at the 2014 College of American Pathologists annual meeting in Chicago, Ill. Myriad myPath Melanoma is a novel diagnostic test that differentiates malignant melanoma from benign skin lesions with greater than 90 percent accuracy and helps physicians deliver a more objective and confident diagnosis for patients.

    Comment?

  8. Myriad myPath melanoma test reduced indeterminate cases by 76 percentRead the original story w/Photo

    Sep 8, 2014 | EurekAlert!

    Myriad Genetics, Inc. today presented results from a pivotal clinical utility study of the Myriad myPath Melanoma test at the 2014 College of American Pathologists annual meeting in Chicago, Ill. Myriad myPath Melanoma is a novel diagnostic test that differentiates malignant melanoma from benign skin lesions with greater than 90 percent accuracy and helps physicians deliver a more objective and confident diagnosis for patients.

    Comment?

  9. Myriad Genetics Receives Average Rating of "Hold" from BrokeragesRead the original story w/Photo

    Sep 8, 2014 | AmericanBankingNews.com

    Myriad Genetics has been given a consensus rating of "Hold" by the seventeen ratings firms that are currently covering the company, American Banking News.com reports . One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company.

    Comment?

  10. Myriad Publishes myRisk Hereditary Cancer Study In CancerRead the original story w/Photo

    Sep 3, 2014 | Benzinga

    Myriad Genetics, Inc. , today announced that the Myriad myRiska Hereditary Cancer test significantly improved the detection of cancer-causing mutations by 46 percent in patients with breast cancer in a new study published in the journal Cancer .

    Comment?

  11. Short Interest in Myriad Genetics Drops By 4.2%Read the original story w/Photo

    Sep 3, 2014 | AmericanBankingNews.com

    Myriad Genetics was the target of a significant drop in short interest during the month of August.

    Comment?

  12. Myriad Genetics to Present at the Morgan Stanley Healthcare ConferenceRead the original story w/Photo

    Aug 28, 2014 | GlobeNewswire

    Myriad Genetics, Inc. announced today that Mark Capone, president of Myriad Genetics Laboratories, is scheduled to present at the Morgan Stanley Healthcare Conference at 9:45 a.m. Eastern time on September 10, 2014, at the Grand Hyatt in New York City.

    Comment?

  13. Critical Alerts For Vodafone Group, Tim Hortons, Transocean, Myriad...Read the original story

    Aug 27, 2014 | Sys-Con Media

    To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

    Comment?

  14. Myriad Genetics' Patents Are Facing Trouble AgainRead the original story

    Aug 25, 2014 | Seeking Alpha

    As I noted earlier, the 2013 Supreme Court ruling declared that isolated human genes are not patentable, which significantly challenged Myriad's patent landscape.

    Comment?

  15. Molecular diagnostics is an important tool for HLA Testing, Food...Read the original story

    Aug 14, 2014 | Release News

    Renub Research has announced the addition of the "United States - Molecular Diagnostics Market, Test Volume Forecast & Companies" report to its offering United States - Molecular Diagnostics Market - Key Facts Covered a The molecular diagnostic market in US is anticipated to be more than double by 2018.

    Comment?

  16. Credit Suisse Reiterates "Neutral" Rating for Myriad GeneticsRead the original story w/Photo

    Aug 15, 2014 | AmericanBankingNews.com

    's stock had its "neutral" rating reaffirmed by equities researchers at Credit Suisse in a research report issued on Friday.

    Comment?

  17. Myriad Genetics Guidance Disappoints, Q4 Edges ViewsRead the original story

    Aug 12, 2014 | Investor's Business Daily

    Gene-tester Myriad Genetics modestly beat fiscal Q4 estimates late Tuesday, but EPS guidance below consensus sent the stock falling 5% in after-hours trading.

    Comment?

  18. Myriad issues weak guidanceRead the original story

    Aug 12, 2014 | Investor's Business Daily

    The molecular diagnostics company beat fiscal Q4 revenue forecasts but full-year guidance fell short.

    Comment?

  19. Myriad Genetics Sees Unusually High Options VolumeRead the original story w/Photo

    Aug 12, 2014 | AmericanBankingNews.com

    Myriad Genetics saw some unusual options trading on Tuesday. Traders acquired 557 call options on the company, AmericanBankingNews.com reports.

    Comment?

  20. Traders Buy Large Volume of Put Options on Myriad GeneticsRead the original story w/Photo

    Aug 12, 2014 | AmericanBankingNews.com

    Shares of Myriad Genetics were the target of some unusual options trading activity on Tuesday.

    Comment?